A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2

Thumbnail
Name:
Publisher version
Authors
Dickey, John B.
Albert, Elisabeth
Badr, Mai
Laraja, Kristin M.
Sena, Laureen M.
Gerson, David S.
Saucedo, Jason E.
Qureshi, Waqas
Aurigemma, Gerard P.
UMass Chan Affiliations
Department of Pediatrics, Division of Pediatric Cardiology
Department of Medicine, Division of Cardiovascular Medicine
Document Type
Response or Comment
Publication Date
2021-09-01
Keywords
SARS-CoV-2
COVID-19
vaccines
myocarditis
Cardiology
Cardiovascular Diseases
Immunology and Infectious Disease
Infectious Disease
Virus Diseases

Metadata
Show full item record
Link to Full Text
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219373/
Abstract
Wide availability of the 3 vaccines approved by the U.S. Food and Drug Administration for emergency use against SARS-CoV-2 has led to reports of adverse reactions not seen during clinical trials: We now report a series of patients who developed CMR-proven myocarditis shortly after vaccination.
Source

Dickey JB, Albert E, Badr M, Laraja KM, Sena LM, Gerson DS, Saucedo JE, Qureshi W, Aurigemma GP. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging. 2021 Sep;14(9):1862-1863. doi: 10.1016/j.jcmg.2021.06.003. Epub 2021 Jun 16. PMID: 34246585; PMCID: PMC8219373. Link to article on publisher's site
DOI
10.1016/j.jcmg.2021.06.003
Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27508
PubMed ID
34246585
Related Resources

Link to Article in PubMed
Collections